Deutsche Bank AG Raises Stock Holdings in BioNTech SE (NASDAQ:BNTX)

Deutsche Bank AG raised its holdings in BioNTech SE (NASDAQ:BNTX) by 2.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 304,500 shares of the company’s stock after purchasing an additional 6,749 shares during the period. Deutsche Bank AG owned about 0.13% of BioNTech worth $34,698,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its stake in BioNTech by 632.6% during the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 501,897 shares of the company’s stock valued at $57,191,000 after buying an additional 433,388 shares in the last quarter. Crestline Management LP bought a new position in shares of BioNTech in the 4th quarter worth about $943,000. Braidwell LP boosted its holdings in shares of BioNTech by 25.1% in the 4th quarter. Braidwell LP now owns 309,865 shares of the company’s stock valued at $35,309,000 after buying an additional 62,115 shares during the period. Bridgefront Capital LLC bought a new stake in shares of BioNTech during the 4th quarter valued at about $284,000. Finally, Baker BROS. Advisors LP bought a new stake in shares of BioNTech during the 4th quarter valued at about $5,131,000. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

BioNTech Stock Down 2.8%

Shares of BioNTech stock opened at $94.50 on Wednesday. The company has a market capitalization of $22.68 billion, a P/E ratio of -45.00 and a beta of 1.35. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The business has a 50-day moving average of $98.12 and a two-hundred day moving average of $109.29. BioNTech SE has a 1 year low of $76.53 and a 1 year high of $131.49.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.70. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.24 billion. During the same period in the prior year, the business earned $1.90 EPS. The company’s revenue for the quarter was down 19.5% compared to the same quarter last year. As a group, equities analysts predict that BioNTech SE will post -3.88 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on BNTX shares. HC Wainwright reduced their price objective on BioNTech from $150.00 to $145.00 and set a “buy” rating for the company in a research report on Tuesday, April 1st. BMO Capital Markets boosted their target price on shares of BioNTech from $130.00 to $143.00 and gave the company an “outperform” rating in a research note on Tuesday, March 11th. Canaccord Genuity Group restated a “buy” rating and issued a $171.44 price target on shares of BioNTech in a research note on Tuesday, March 11th. Morgan Stanley reduced their price objective on BioNTech from $140.00 to $132.00 and set an “overweight” rating for the company in a research report on Tuesday, May 6th. Finally, Citigroup restated a “buy” rating and issued a $140.00 target price (down from $145.00) on shares of BioNTech in a research report on Tuesday, May 6th. Three research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $142.73.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.